Cardiac allograft vasculopathy prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 13: | Line 13: | ||
** [[Cyclosporine]] | ** [[Cyclosporine]] | ||
** [[Tacrolimus]] | ** [[Tacrolimus]] | ||
* [[Rapamycin]] | * [[Immunosuppressive drugs#Drugs Acting on Immunophilins|Rapamycin derivatives]], such as | ||
** [[Sirolimus]] | ** [[Sirolimus]] | ||
** [[Everolimus]] | ** [[Everolimus]] | ||
Revision as of 19:22, 1 October 2014
Template:Cardiac Allograft Vasculopathy Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2] Raviteja Guddeti, M.B.B.S. [3]
Overview
Prevention
As the pathogenesis of CAV consists of both immunological and non-immunological insults, preventative strategies should consist of control of risk factors for CAV and optimal immunosuppressive therapy.
Optimization of Immunosuppressive Therapy
Options for immunosuppressive therapy for prevention of CAV includes:
- Calcineurin inhibitors, such as
- Rapamycin derivatives, such as
- Corticosteroids
- Azathioprine
- Mycophenolate mofetil